{
    "title": "AstraZeneca boasts positive results from drug trial involving late-stage endometrial cancer patients",
    "url": "https://www.dailymail.co.uk/money/markets/article-12127659/AstraZeneca-announces-good-results-endometrial-cancer-trial.html",
    "date": "2023-05-26",
    "keywords": [
        "cancer",
        "cent",
        "drug",
        "giant",
        "imfinzi",
        "lynparza",
        "astrazeneca",
        "share",
        "fund",
        "trial",
        "oncology",
        "covid19",
        "condition",
        "month",
        "investment",
        "account",
        "fee",
        "chemotherapy",
        "gain",
        "survival",
        "benefit",
        "part",
        "treatment",
        "outcomesimfinzi",
        "durvalumab",
        "lung",
        "bile",
        "duct",
        "gallbladder",
        "name",
        "prostate",
        "breast",
        "cancersastrazeneca",
        "year",
        "half",
        "divisionsusan",
        "vicepresident",
        "research",
        "development",
        "ambition",
        "care",
        "combination",
        "base",
        "britain",
        "drugmaker",
        "boss",
        "soriot",
        "pharma",
        "article",
        "form",
        "world",
        "health",
        "organisation",
        "afternoon",
        "value",
        "start",
        "yearin",
        "firstquarter",
        "ftse",
        "firm",
        "turnover",
        "plunge",
        "travel",
        "performance",
        "outlook",
        "revenue",
        "percentage",
        "diy",
        "capital",
        "risk",
        "isa",
        "trade",
        "community",
        "model",
        "affiliate",
        "product",
        "money",
        "commission",
        "editorial",
        "independence",
        "investing",
        "platform"
    ],
    "category": [
        "money",
        "markets"
    ]
}